https://orcid.org/0000-0002-9384-7387
References
- Risau W. Mechanisms of angiogenesis. Nature 386(6626), 671–674 (1997).
- Rao N, Lee YF, Ge R. Novel endogenous angiogenesis inhibitors and their therapeutic potential. Acta Pharmacol. Sin. 36(10), 1177–1190 (2015).
- Barui AK, Nethi SK, Haque S, Basuthakur P, Patra CR. Recent development of metal nanoparticles for angiogenesis study and their therapeutic applications. ACS Appl. Bio Mater. 2(12), 5492–5511 (2019).
- World Health Organisation. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 (2020). http://www.iarc.fr/featured-news/latest-global-cancer-data-cancer-burden-rises-to-18-1-million-new-cases-and-9-6-million-cancer-deaths-in-2018
- Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182–1186 (1971).
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1), 27–30 (1995).
- Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
- Van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol. Rev. 67(2), 441–461 (2015).
- Mukherjee P, Bhattacharya R, Wang P et al. Antiangiogenic properties of gold nanoparticles. Clin. Cancer Res. 11(9), 3530–3534 (2005).
- Gurunathan S, Lee K-J, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom SH. Antiangiogenic properties of silver nanoparticles. Biomaterials 30(31), 6341–6350 (2009).
- Song H, Wang W, Zhao P, Qi Z, Zhao S. Cuprous oxide nanoparticles inhibit angiogenesis via down regulation of VEGFR2 expression. Nanoscale 6(6), 3206–3216 (2014).
- Giri S, Karakoti A, Graham RP et al. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PloS ONE 8(1), e54578 (2013).
- Das S, Roy A, Barui AK et al. Anti-angiogenic vanadium pentoxide nanoparticles for the treatment of melanoma and their in vivo toxicity study. Nanoscale 12(14), 7604–7621 (2020).
- Ivanković S, Musić S, Gotić M, Ljubešić N. Cytotoxicity of nanosize V2O5 particles to selected fibroblast and tumor cells. Toxicol. In Vitro 20(3), 286–294 (2006).
- Deepika P, Vinusha H, Muneera B, Rekha N, Prasad KS. Vanadium oxide nanorods as DNA cleaving and anti-angiogenic agent: novel green synthetic approach using leaf extract of Tinospora cordifolia. Curr. Res. Green Sustain. Chem. 1-2, 14–19 (2020).
- Rehder D. The role of vanadium in biology. Metallomics 7(5), 730–742 (2015).
- Nriagu JO. History, occurrence, and uses of vanadium. In: Vanadium in the Environment, Part 1 Chemistry andBiochemistry Nriagu JO ( Ed.). Wiley-Interscience, NJ, USA, 1–36 (1998).
- Hansen TV, Aaseth J, Alexander J. The effect of chelating agents on vanadium distribution in the rat body and on uptake by human erythrocytes. Arch. Toxicol. 50(3–4), 195–202 (1982).
- Chatterjee M, Das S, Chatterjee M, Roy K. Vanadium in biological systems. In: Encyclopedia of Metalloproteins Kretsinger RH, Uversky VN, Permyakov EA ( Eds). Springer, NY, USA, 2293–2297 (2013).
- Zirlik K, Duyster J. Anti-angiogenics: current situation and future perspectives. Oncol. Res. Treat. 41(4), 166–171 (2018).